Core Insights - Tempus AI's strategic focus for 2026 is on expanding its AI-driven precision medicine platform, scaling the diagnostics business, enhancing data and AI capabilities, and strengthening relationships with healthcare providers and pharmaceutical companies, supported by a commercial pipeline with a total contract value exceeding $1.1 billion [2] Financial Performance - In 2025, Tempus reported total revenues of $1.3 billion, an increase of 83.4% year over year, with the Diagnostics segment generating $955.4 million, reflecting 111.5% year-over-year growth, driven by strong Oncology and Hereditary testing volumes [3][8] - The Data and Applications segment also saw significant growth, generating $316.4 million in revenues, up 30.9% year over year, attributed to strong momentum in the Insights data licensing business [3] Market Position and Competitors - Tempus peers, such as Inspire Medical Systems and 10x Genomics, are expected to maintain growth momentum, with Inspire benefiting from increased adoption of sleep apnea therapy devices and 10x advancing through demand for single-cell and spatial genomics technologies [4] Stock Performance - Over the past year, Tempus shares increased by 15.7%, contrasting with a 25.2% decline in the Zacks Medical Info Systems industry, while peers like Inspire Medical Systems saw a 64.9% drop, and 10x Genomics posted a gain of 96.5% [5] Growth Initiatives - Tempus anticipates strong growth in its oncology diagnostics segment, expecting a 30% growth rate driven by the increasing adoption of genomic sequencing in cancer care, supported by a comprehensive test portfolio [6][9] - The company is also focusing on scaling the Minimal Residual Disease (MRD) testing opportunity, which has shown a 56% quarter-over-quarter volume growth, with plans for gradual commercialization and reimbursement coverage [10][11] Clinical Applications and Software Development - Beyond diagnostics, Tempus is developing clinical applications and healthcare software, including AI-powered tools like TIME and Next, aimed at enhancing patient matching and care pathway intelligence, which will create new revenue opportunities and strengthen its data ecosystem [12] Future Outlook - According to the Zacks Consensus Estimate, Tempus is expected to see a 25.4% improvement in revenues for 2026, although earnings per share are projected to remain negative but improve by 39.3% over 2025 [13]

Financial Data and Key Metrics Changes - In 2025, the company achieved over 7% top-line growth and 13% adjusted EPS growth, with margins improving by over 50 basis points [5][13] - For the fourth quarter, enterprise revenue increased by 5.6% year-over-year, with adjusted EPS growing by 18% [10][14] - Free cash flow from continuing operations was $490 million, a decrease from $665 million the previous year, primarily due to working capital timing [15] Business Line Data and Key Metrics Changes - Diagnostics revenue for the fourth quarter was $2.7 billion, up 5.5% year-over-year, with organic growth of 4.1% [16] - Biopharma Laboratory Services (BLS) revenue increased by 3.4% year-over-year, with central lab revenue growing by 11.1% [17] - The adjusted operating income for diagnostics was $419 million, representing 15.4% of revenue, compared to 13.9% the previous year [16] Market Data and Key Metrics Changes - The company reported a strong trailing twelve-month book-to-bill ratio of 1.09, driven by central labs [13][18] - The backlog for BLS was $8.7 billion, with an expected conversion of approximately $2.7 billion into revenue over the next 12 months [18] Company Strategy and Development Direction - The company aims to deepen partnerships with health systems and local laboratories, having signed or closed 13 deals contributing to over $1 billion in revenue growth [5][6] - A strategic investment is planned for a new central laboratory facility to support growth and demand, with construction expected to begin later this year [9] - The company continues to focus on specialty testing, having launched over 130 new tests in 2025, particularly in oncology, women's health, and neurology [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong underlying business performance for 2026, expecting enterprise revenue growth of 5.4% and adjusted EPS growth of approximately 9% [11][20] - The delay of PAMA through December 31, 2026, was viewed positively, but management emphasized the need for permanent reform [11][20] - Management highlighted the importance of ongoing investments in technology and AI to enhance customer experience and operational efficiency [9][21] Other Important Information - The company plans to allocate free cash flow for acquisitions, share repurchases, and dividends, with approximately $800 million of share repurchase authorization remaining [15][21] - Two executives are set to retire on April 1, with successors already appointed [11][12] Q&A Session Summary Question: 2026 guidance contributions from price and volume - Management expects revenue growth of 5%-6% in diagnostics, with half of the organic growth coming from volume and half from price mix [26][27] Question: Contributions from Invitae integration - The integration of Invitae has been successful, with expected revenue growth in specialty areas, but specific breakout of Invitae's performance will no longer be provided [31][32] Question: Fourth quarter organic volume performance - Organic volume was impacted by lower referrals from a large consumer genetic client and weather conditions, but adjustments indicate growth would have been over 2% [36][37] Question: 2026 guidance conservativeness and risks - Management feels confident about the guidance but acknowledges potential variability in organic volumes and the timing of M&A [44][46] Question: Competitive landscape in diagnostics - The company believes it will outperform the overall market, focusing on hospital deals and specialty testing, which are expected to grow faster than the overall market [48][49] Question: PAMA implications and central lab investments - Management is prepared to submit data for PAMA and continues to advocate for the RESULTS Act, while also planning significant investments in central lab infrastructure [55][59]

Financial Data and Key Metrics Changes - In 2025, the company achieved over 7% top-line growth and 13% adjusted EPS growth, with margins improving by over 50 basis points [5][13] - For the fourth quarter, enterprise revenue increased by 5.6% year-over-year, with adjusted EPS growing by 18% [10][14] - Free cash flow for the quarter was $490 million, down from $665 million the previous year, primarily due to working capital timing [15] Business Line Data and Key Metrics Changes - Diagnostics revenue for the fourth quarter was $2.7 billion, up 5.5% year-over-year, with organic growth of 4.1% [16] - Biopharma Laboratory Services (BLS) revenue increased by 3.4%, with Central Labs performing well and revenue growing 11.1% [17] - The adjusted operating income for Diagnostics was $419 million, or 15.4% of revenue, compared to $316 million, or 13.9% of revenue last year [16] Market Data and Key Metrics Changes - The company reported a strong trailing 12-month book-to-bill ratio of 1.09, driven by Central Labs [13][18] - The backlog for BLS was $8.7 billion, with an expectation of approximately $2.7 billion converting into revenue over the next 12 months [18] Company Strategy and Development Direction - The company aims to deepen partnerships with health systems and local laboratories, having signed or closed 13 deals contributing to over $1 billion in revenue growth [5][6] - A strategic investment is planned for a new central laboratory facility to support growth and demand, with construction expected to begin later this year [9][21] - The company continues to focus on specialty testing, having launched over 130 new tests in 2025, particularly in oncology, women's health, and neurology [7][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong underlying business performance for 2026, expecting full-year enterprise revenue growth of 5.4% and adjusted EPS growth of approximately 9% [11][20] - The delay of PAMA through December 31, 2026, was viewed positively, but management emphasized the need for permanent reform [11][56] - Management noted that the diagnostic market remains strong, with expectations to outperform overall market growth [48] Other Important Information - The company announced the retirement of two executive vice presidents, effective April 1, with successors appointed [12] - The company plans to reinvest a portion of the savings from the PAMA delay into its business for long-term growth [88] Q&A Session Summary Question: Guidance for 2026 contributions from price and volume - Management expects revenue growth of 5%-6% in diagnostics, with half of the organic growth coming from volume and half from price mix [27][30] Question: Contributions from Invitae integration - The integration of Invitae has gone well, with expected revenue growth in specialty areas, but specific breakout of Invitae's performance will no longer be provided [32] Question: Fourth quarter organic volume performance - Organic volume growth was impacted by lower referrals from a large consumer genetic client and weather conditions, but adjustments indicate consistent growth [36][39] Question: Competitive landscape in diagnostics - Management believes the diagnostic market is strong, with a focus on hospital partnerships and specialty testing driving growth [48] Question: PAMA implications and survey submission - Management is prepared to submit data for PAMA and continues to advocate for the RESULTS Act as a permanent solution [55][56] Question: Early Development market growth and pricing - Early Development is expected to remain flat in 2026, with ongoing consolidation efforts to improve margins [66] Question: New oncology tests and revenue expectations - The company is well-positioned in precision oncology testing, with expectations for strong growth in new tests launched [69]

Financial Data and Key Metrics Changes - In 2025, Labcorp achieved over 7% top-line growth and 13% adjusted EPS growth, with margins improving by over 50 basis points [4][12] - For Q4 2025, enterprise revenue increased by 5.6% to $3.5 billion, with adjusted EPS growing 18% to $4.07 [13][9] - Free cash flow for the year was $1.2 billion, a 10% increase, while Q4 free cash flow was $490 million, down from $665 million due to working capital timing [12][14] Business Line Data and Key Metrics Changes - Diagnostics revenue for Q4 was $2.7 billion, up 5.5% year-over-year, with organic growth of 4.1% and acquisitions contributing 1.5% [15] - Biopharma Laboratory Services (BLS) revenue increased by 3.4% to $793 million, with central lab revenue growing 11.1% [16] - Adjusted operating income for diagnostics was $419 million (15.4% of revenue), while BLS adjusted operating income was $136 million (17.2% of revenue) [15][17] Market Data and Key Metrics Changes - The central laboratory business saw strong demand, particularly in oncology and neurology, with a trailing twelve-month book-to-bill ratio of 1.09 [9][17] - Esoteric testing accounted for 41.5% of total testing revenue in Q4, reflecting a growing trend in specialty testing [93] Company Strategy and Development Direction - Labcorp is focusing on deepening partnerships with health systems and local laboratories, having signed 13 deals that contributed over $1 billion in revenue [4][5] - The company is advancing its leadership in specialty testing, launching over 130 new tests in 2025, particularly in oncology, women's health, and neurology [6][7] - A new central laboratory facility is planned to support growth, with construction expected to begin later this year [8][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong underlying business performance for 2026, expecting enterprise revenue growth of 5.4% and adjusted EPS growth of approximately 9% [10][19] - The delay of PAMA until December 31, 2026, is seen as a positive development, but management continues to advocate for the passage of the RESULTS Act [10][54] - Management noted that the utilization environment remains healthy, driven by an aging population and increased testing [44] Other Important Information - The company plans to invest approximately 4% of revenue in capital expenditures in 2026, higher than previous years, to support long-term growth [56][20] - Two executives, Mark Schroeder and Sandy van der Vaart, will retire on April 1, with successors already appointed [10][11] Q&A Session Summary Question: How are you thinking about contributions from price and volume in 2026 guidance? - Management expects revenue growth of 5%-6% in diagnostics, with half of the organic growth coming from volume and half from price mix [25][26] Question: What are the contributions from Invitae this year? - The integration of Invitae has gone well, and it is expected to grow revenue at two to three times the overall market rate, but will not be broken out separately [29][30] Question: What impacted the fourth quarter organic volume? - Lower referrals from a large consumer genetic client and weather conditions affected organic volume, but adjustments indicate growth would have been over 2% [33][34] Question: Where do you see the biggest risks in 2026 guidance? - Risks include slightly higher or lower organic volumes and the timing of M&A impacting revenue [42][44] Question: How do you view the competitive landscape in the diagnostic business? - Management believes the diagnostic market is strong, with Labcorp expected to outperform overall market growth, particularly in specialty testing [46][47] Question: What is the status of PAMA and its impact? - The delay of PAMA is seen positively, and management will continue to advocate for the RESULTS Act while preparing to submit necessary data [53][54] Question: Can you discuss the early development business and market growth? - The early development business is expected to be relatively flat in 2026, with improvements anticipated as consolidation efforts progress [64][66]

Company Overview - Twist Bioscience's stock has experienced a significant rebound in recent months, attributed to increasing optimism surrounding AI-enabled drug discovery and the adoption of minimal residual disease (MRD) testing [1] - The Biopharma segment of Twist is reaccelerating, driven by customers engaged in AI-enabled drug discovery and next-generation sequencing (NGS) [1] Investment Strategy - Narweena, an asset management firm led by Richard Durant, focuses on identifying market dislocations caused by a poor understanding of long-term business prospects, aiming for excess risk-adjusted returns [1] - The research process at Narweena emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and a long-term investment horizon [1] - The firm targets smaller cap stocks and markets where competitive advantages are not immediately apparent, driven by the belief that an aging population and low growth will create new investment opportunities [1] Market Dynamics - Many industries are expected to face stagnation or secular decline, which may paradoxically enhance business performance due to reduced competition [1] - Conversely, some businesses may encounter rising costs and diseconomies of scale, impacting their performance negatively [1] - The economy is increasingly characterized by asset-light businesses, leading to a declining need for infrastructure investments over time [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [1] Leadership Background - Richard Durant holds undergraduate degrees in engineering and finance from the University of Adelaide and an MBA from Nanyang Technological University, where he was on the Dean's Honors List [1] - He has successfully passed the CFA exams, indicating a strong foundation in financial analysis [1]

Company Overview - Twist Bioscience's stock has experienced a significant rebound in recent months, attributed to increasing optimism surrounding AI-enabled drug discovery and the adoption of minimal residual disease (MRD) testing [1] - The Biopharma segment of Twist is reaccelerating, driven by customers engaged in AI-enabled drug discovery and next-generation sequencing (NGS) [1] Investment Strategy - Narweena, an asset management firm led by Richard Durant, focuses on identifying market dislocations caused by a poor understanding of long-term business prospects, aiming for excess risk-adjusted returns [1] - The research process at Narweena emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and a long-term investment horizon [1] - The firm targets smaller cap stocks and markets where competitive advantages are not immediately apparent, driven by the belief that an aging population and low growth will create new investment opportunities [1] Market Dynamics - Many industries are expected to face stagnation or secular decline, which may paradoxically enhance business performance due to reduced competition [1] - Conversely, some businesses may encounter rising costs and diseconomies of scale, impacting their performance negatively [1] - The economy is increasingly characterized by asset-light businesses, leading to a declining need for infrastructure investments over time [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [1]